Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Bioporto - Præsentation af Q3 2025 (Optagelse)

By Michael FriisHead of Equities
BioPorto

I dag havde vi fornøjelsen af et event med CEO Carsten Buhl samt CFO Niels Høy Nielsen, som præsenterede de finansielle resultater og begivenheder fra 3. kvartal. Et kvartal, der blandt andet bød på en ny strategiplan med opdaterede finansielle målsætninger samt en gennemført kapitalforhøjelse, der sikrer kapital frem til 2026 til at udmønte de fremlagte planer. Præsentationen blev efterfulgt af en Q&A-session.

Se eventet her: Q3 2025 Event

Disclaimer: HC Andersen Capital modtager betaling fra Bioporto for en Digital IR/Corporate Visibility abonnementsaftale./Michael Friis 19/11-2025 kl. 16.15

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.